Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
... are the details on each of these data presentations.
on June 10, 2009, Dr. Todd Swick will be presenting a poster entitled "Impa...ial of Sodium Oxybate" in the 10:15 am-12:15 pm poster session.
on June 11, 2009 at 9:00 am in Ballroom 6E, Dr. Swick will also deliver an ...
Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June
...ess, physical health and longevity, said Dr. Michael Vitiello, chair of the apss
program committee. The information presented during SLEEP 2008 will help t... and the Sleep Research Society. In addition to organizing SLEEP 2008, the apss
also publishes Sleep, a monthly peer-reviewed scientific journal.
Greenway Medical Technologies Strengthens Industry Leadership With Participation in the IHE Connectathon and HIMSS Interoperability Showcase
...ice revenue and enhance improvements in patient care and
overall population health while facilitating public health research and
quality measures like apss
To enhance the success and adoption of these two initiatives, Greenway
is also promoting Cross-Enterprise Document Sharing (XDS.b), which ...
Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
...ere headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis.
Additional details on the data presented at the 2009 apss
can be found at http://www.journalsleep.org/PDF/AbstractBook2009.pdf (abstract 0984, p.354).
Jazz Pharmaceuticals ha...
Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
...ons of available therapies," said Dr. Roth, who participated in a
June 2008 apss
symposium convened to discuss the prevalence and
consequences of nocturnal ...ew Approach for Patients with Middle of the Night
In a related apss
poster presentation, investigators described a study
in which they sought t...
Neurogen Proprietary Insomnia Compound Data Presented at Associated
Professional Sleep Societies Annual Meeting
... Minnesota. Two Phase 2b clinical studies
with NG2-73 in chronic insomnia patients are currently being
conducted by the Company. Data presented at the apss
includes the following:
"Safety and Tolerability in Early Phase I Studies of NG2-73, a
Novel GABA(A) Sleep Agent"
NG2-73 is a GABA(A)...
Neurocrine Biosciences Announces New Research Studies Presented at
APSS Reveal Significant Under-Diagnosis of Insomnia
Sleep Societies (APSS) Annual Meeting. apss
highlights show that
insomnia is significantly und...care System and Labor Force. New data presented
demonstrates the significant impact insomnia has o... Medical Officer of Neurocrine
Study Demonstrates ...
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and
Maintenance vs. Placebo
staying asleep longer," said Tom Roth, Ph.D., Director of the Henry
Ford Sleep Disorders and Research Center in Detroit, MI, presenter
at today's apss
session. "These subjective measures support data
collected in the sleep lab and provide an important dimension for
assessing the efficacy of VEC-162."...